SOX6 is a Novel Immunohistochemical Marker for Differential Diagnosis of Epithelioid Mesothelioma From Lung Adenocarcinoma.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
5
6
2020
medline:
21
10
2020
entrez:
5
6
2020
Statut:
ppublish
Résumé
The differential diagnosis of epithelioid mesothelioma from lung adenocarcinoma using immunohistochemistry is improving. However, immunohistochemical markers with high sensitivity and specificity have yet to be identified. In this study, we investigated the utility of sex-determining region Y box 6 (SOX6) as a novel immunohistochemical marker, identified by analyzing previous gene expression data. Immunohistochemically, SOX6 expression was present in 53 of 54 (98%) cases of epithelioid mesothelioma, compared with its expression in only 5 of 69 (7%) cases of lung adenocarcinoma. The sensitivity and specificity of SOX6 expression for differentiating epithelioid mesothelioma and lung adenocarcinoma were 98% and 93%, respectively. SOX6 expression showed similar sensitivity and far better specificity than those of calretinin or podoplanin (D2-40). In addition, SOX6 expression was more sensitive than Wilms' tumor 1 expression. The combination of SOX6 with other markers showed comparable or better sensitivity and specificity relative to other combinations. In particular, the sensitivity of positivity for both SOX6 and calretinin (96%) and the specificity of positivity for both SOX6 and Wilms' tumor 1 (93%) were higher than those of the other combinations. In conclusion, SOX6 is a novel candidate immunohistochemical marker for differentiating epithelioid mesothelioma from lung adenocarcinoma.
Identifiants
pubmed: 32496433
doi: 10.1097/PAS.0000000000001507
pii: 00000478-202009000-00012
doi:
Substances chimiques
Biomarkers, Tumor
0
SOX6 protein, human
0
SOXD Transcription Factors
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1259-1265Références
Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591–1603.
Delgermaa V, Takahashi K, Park EK, et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89:716–724.
Galateau-Salle F, Churg A, Roggli V, et alTravis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Epithelioid mesothelioma. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC; 2015:156–164.
Attanoos RL, Gibbs AR. ‘Pseudomesotheliomatous’ carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff. Histopathology. 2003;43:444–452.
Travis WD, Noguchi M, Yatabe Y, et alTravis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Adenocarcinoma. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC; 2015:26–37.
Takeshima Y, Inai K, Amatya VJ, et al. Accuracy of pathological diagnosis of mesothelioma cases in Japan: clinicopathological analysis of 382 cases. Lung Cancer. 2009;66:191–197.
Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018;142:89–108.
Kai Y, Amatya VJ, Kushitani K, et al. Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma. Histopathology. 2019;74:545–554.
Kuraoka M, Amatya VJ, Kushitani K, et al. Identification of DAB2 and intelectin-1 as novel positive immunohistochemical markers of epithelioid mesothelioma by transcriptome microarray analysis for its differentiation from pulmonary adenocarcinoma. Am J Surg Pathol. 2017;41:1045–1052.
Hamada-Kanazawa M, Ishikawa K, Ogawa D, et al. Suppression of Sox6 in P19 cells leads to failure of neuronal differentiation by retinoic acid and induces retinoic acid-dependent apoptosis. FEBS Lett. 2004;577:60–66.
Iguchi H, Urashima Y, Inagaki Y, et al. SOX6 suppresses cyclin D1 promoter activity by interacting with beta-catenin and histone deacetylase 1, and its down-regulation induces pancreatic beta-cell proliferation. J Biol Chem. 2007;282:19052–19061.
Zhou Y, Zheng X, Chen LJ, et al. microRNA-181b suppresses the metastasis of lung cancer cells by targeting sex determining region Y-related high mobility group-box 6 (SOX6). Pathol Res Pract. 2019;215:335–342.
Guo X, Yang M, Gu H, et al. Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinoma. Cancer Epidemiol. 2013;37:732–736.
Li Y, Xiao M, Guo F. The role of Sox6 and Netrin-1 in ovarian cancer cell growth, invasiveness, and angiogenesis. Tumour Biol. 2017;39:1010428317705508.
Qin YR, Tang H, Xie F, et al. Characterization of tumor-suppressive function of SOX6 in human esophageal squamous cell carcinoma. Clin Cancer Res. 2011;17:46–55.
Wang J, Ding S, Duan Z, et al. Role of p14ARF-HDM2-p53 axis in SOX6-mediated tumor suppression. Oncogene. 2016;35:1692–1702.
Mawas AS, Amatya VJ, Kushitani K, et al. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung. Sci Rep. 2018;8:134.
Amatya VJ, Kushitani K, Kai Y, et al. Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Mod Pathol. 2018;31:809–815.